Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

From RESI Boston to Global Growth: Bilix on Winning the Innovator’s Pitch Challenge

15 Oct
Myung Kim
   CaitiCaitlin Dolegowski

Bilix, recognized as a top Innovator’s Pitch Challenge winner at RESI Boston this past September, is making waves in the biotech space with its innovative multi-modality approach to inflammatory and autoimmune diseases. In this interview, Myung Kim, Founder and CEO, shares how participating in RESI Boston helped the company connect with key investors, refine its strategy, and advance its clinical milestones.

Hear firsthand how Bilix is driving progress in complex disease treatment and discover how your company can join the next generation of innovators pitching at RESI London and RESI JPM. Applications are now open.

Apply to Pitch at RESI London Apply to Pitch at RESI JPM

Tags: , , , , , , , , , , , , , , , , , , , , ,

Five Leading Life Science Organisations Collaborate on Inaugural London Bio-Innovation Week 

7 Oct

By Tony Jones, CEO, One Nucleus (Special Guest Contributor)

ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and SLAS will provide delegates with the opportunity for cross-event partnering during London Bio-Innovation week, which runs 1-5 December, 2025

One Nucleus’ Genesis conference partnering app open to delegates attending any of Bio-Innovation Week events

Initiative to provide extended opportunities for networking, to support the life science ecosystem


London, UK, 30 September 2025: ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and The Society for Laboratory Automation and Screening (SLAS) today announced that they will be collaborating during London Bio-Innovation week, to facilitate multi-event networking and partnering opportunities for life science companies.

London Bio-Innovation week, which runs 1-5 December, 2025, will see each of the five organisations delivering events in the UK’s capital city. While each event is being run independently, collectively their co-location in one city provides a unique opportunity to meet with in excess of 1000 of the brightest science and business minds in London that week.

To further support those seeking new collaborations, insights and opportunities, the event organisers will provide the opportunity for cross-event partnering. Delegates attending any one of the Bio-Innovation Week events will be able to access the One Nucleus Genesis app, to connect with delegates attending different conferences.

Tony Jones, CEO, One Nucleus, said: “Collaboration sits at the core of translating world leading bioscience research into new ventures developing innovative products and technologies to improve patient outcomes. With so much activity in London for Bio-Innovation Week, we identified a unique opportunity to support the life science sector, by opening the Genesis conference partnering app to both attendees and non-attendees, providing a platform for partnering across the multiple events.”

London Bio-Innovation Week Events:

About ELRIG https://elrig.org/

ELRIG are proud to be a leading European not-for-profit organisation dedicated to uplifting the life science and drug discovery community. Our mission is to foster open access to modern research and innovation. Bringing together our vibrant community of over 12,000 life science professionals from academia and biopharma to connect, collaborate and encourage curiosity.

Contact: Sanj Kumar, CEO sanj.kumar@elrig.org

About Life Science Integrates https://lifescienceintegrates.com/

Formed in 2011 by Christopher Watt and Samuel Thangiah, Life Science Integrates (LSI) brings together Senior Leaders from across the Life Sciences, including industry, academia, government and regulators; providing them with unique opportunities to be part of the conversations that set out the industry’s challenges and identify effective strategies and solutions.

Contact: Samuel Thangiah, Founder and Executive Director samuel.thangiah@lsi-uk.com

About Life Science Nation (RESI) https://www.lifesciencenation.com/

The Redefining Every Stage of Investment (RESI) conference series, provided by Life Science Nation, connects start-ups and investors and strategic licensing partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.

Contact: Greg Manix VP International Business Development g.mannix@lifesciencenation.com

About One Nucleus https://onenucleus.com/

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity.

Contact: Tony Jones, CEO tony@onenucleus.com

About SLAS https://www.slas.org/

The Society for Laboratory Automation and Screening is the global leader in bringing life sciences researchers and laboratory technology providers together under one roof for knowledge sharing and collaboration aimed at transforming research. Annually, SLAS holds its must-attend International Conference & Exhibition in the U.S. and its Europe Conference and Exhibition, with opportunities for start-ups to gain exposure to thousands of potential customers, as well as award opportunities for scientific content by way of poster presentations and the annual Innovation Award. Regular networking events around the world enable regional communities to come together to strengthen research collaboration.

Contact: Vicki Loise, CEO vloise@slas.org or SLAS Europe Ambassador, Manuela Beil-Peter, mbeilpeter@slas.org

Media Contact Information :

Media contact

Lorna Cuddon
Zyme Communications
Tel: +44(0)7811 996 942
Email: lorna.cuddon@zymecommunications.com

Tony Jones, One Nucleus
email: tony@onenucleus.com

Register for RESI London Register for RESI & Genesis Combi Ticket

 

Tags: , , , , , , , , ,

How 100% Pharma Tariffs Could Ripple Through Early-Stage Biotech Investment 

7 Oct

By Sougato Das, President and COO, LSN

Sougato-Das

We have all heard about the recent 100% pharma tariff announcement, applicable mainly to manufacturers or marketed drugs unless they are in the process of building manufacturing facilities in the US. We know that early stage biotechs are generally not counting on investment to take them through manufacturing, for which they will seek a pharma partner. Nevertheless, these tariffs may still have an effect on early-stage biotech investments. Investment in early-stage (seed, Series A/B) biotech is likely to face increased headwinds under a 100 % pharmaceutical tariff regime. The tariff risk exacerbates existing structural challenges in biotech investing.

Overall Expected Effect (Short to Medium Term) 

  • Slower fundraising pace 
    The number of deals may decline, particularly in the earlier stages. Biotech investors will likely become more selective, preferring de-risked assets, strong data, or compelling platforms with clear strategies to mitigate tariff exposure.
  • Higher effective cost of capital 
    Investors will demand more upside or stricter protections (e.g. liquidation preferences, anti-dilution) to compensate for the added risk.
  • Greater emphasis on capital efficiency / leaner burn models 
    Startups may need to conserve cash more, focus earlier on key inflection points, outsource less, and plan fallback strategies for supply chain risk.
  • Longer timelines / delayed exits 
    Because of the risk, uncertainty, and possible delays, the time to IPO, acquisition, or commercialization may stretch, further compressing IRR for investors.
  • Capital flow shift toward infrastructure and enabling technologies 
    Some portion of venture capital may redirect toward bioprocessing, domestic manufacturing, synthetic biology for local API production, supply-chain tools — companies that can help others evade tariff impact.
  • Public market investment in pharma may slow, leading to less IPOs 
    The tariffs could serve to further erode the attractiveness of the biopharma sector for public market investors, reducing the room for IPOs, and pressuring investment taking place more upstream.

In summary, while the recent 100% pharma tariffs certainly don’t have a direct effect on early-stage biotech investing, their dampening effects will nonetheless be felt.

Tags: , , , , , , , , , , , , , , , , ,

Super Early Bird Rates End October 3 for RESI London and RESI JPM 

30 Sep

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation’s Redefining Every Stage of Investments (RESI) conferences are designed to connect life science companies with global investors and strategic partners. Two major upcoming events, RESI London and RESI JPM, are now open for registration at Super Early Bird rates through October 3. By registering early, attendees can save £300 on RESI London and $800 on RESI JPM.

RESI London 2025

The first week of December marks the largest life science partnering and venture week in the UK. If you are raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s RESI London, One Nucleus’ Genesis, and ELRIG/SLAS events offer stronger partnering, investment, learning, and procurement opportunities compared to the health care week in late November that runs alongside the Jefferies investment banking event. That November week typically focuses on recent IPOs, companies close to IPO, and phase 3 or more advanced companies seeking partnerships. For companies not yet at that stage, December’s conference series is a more strategic use of critical conference and travel budgets.

RESI London and Genesis are joining to provide a multi-day investment, partnering, and thought leadership event for venture-stage companies pursuing funding and strategic alliances. RESI London will take place on December 4 at 1 Wimpole Street and 11 Cavendish Square, followed by two days of virtual partnering on December 5 and 6. Super Early Bird registration is now open, offering a savings of £300 until October 3.

RESI JPM 2026

RESI JPM will be held January 12–13, 2026, at the San Francisco Marriott Marquis. The program features two days of in-person investor panels, workshops, networking, and one-on-one partnering, followed by three days of online partnering on January 14, 19, and 20.

Previous RESI JPM conferences have drawn more than one thousand attendees, including over 500 investors, innovators, and industry experts from across the globe. The conference is held concurrently with JP Morgan Healthcare Week, January 12–15, 2026, which takes place at the Westin St. Francis. Known as the largest healthcare investment symposium worldwide, JPM attracts thousands of life science professionals each year.

Super Early Bird registration for RESI JPM offers a savings of $800 when completed before October 3.

Register for RESI London
Register for RESI & Genesis Combi Ticket		 Register for RESI JPM

Both conferences provide access to global investors and in-licensors, strategic partners, and hundreds of early-stage innovators across therapeutics, medical devices, diagnostics, and digital health. Register now to take advantage of Super Early Bird discounts for RESI London and RESI JPM before October 3.

Tags: , , , , , , , , , , , , , , , ,

Investor Panels at RESI JPM 2026 

30 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to announce the lineup of investor panels at RESI JPM 2026, taking place January 12–13. These panels bring together leading venture capitalists, corporate investors, and strategic partners to discuss the latest trends, challenges, and opportunities in life science investing. From early-stage “first check” VCs to specialized sectors like Cell & Gene Therapy, AI in Healthcare, and Longevity, RESI JPM offers unparalleled insight into the funding landscape. 

Day 1 – January 12 

  • 9:00 AM | “First Check” VCs Panel: Learn how early-stage investors evaluate founders, milestones, and the critical first institutional check. 
  • 10:00 AM | Medtech Strategics Panel: Explore how strategic investors from leading medtech companies drive growth through partnerships and acquisitions. 
  • 11:00 AM | Asia Cross Border Investments Panel: Sponsored by Enterprise Singapore, a RESI JPM Title Sponsor
  • 1:00 PM | Family Offices Panel: Hear how family offices provide patient, mission-driven capital to early- and growth-stage companies. 
  • 2:00 PM | Cell & Gene Therapy Panel: Discover where capital is flowing in this transformative area of medicine. 
  • 3:00 PM | When Should Companies Exit Stealth Mode?: Gain insight into timing the transition from quiet development to public visibility. 
  • 4:00 PM | Aging and Longevity Panel: Learn how investors are deploying capital to solutions addressing the world’s aging population. 

Day 2 – January 13 

  • 9:00 AM | Partnering with Global Pharma Panel: Understand how big pharma approaches early-stage partnerships and collaboration. 
  • 10:00 AM | Women’s Health Panel: Explore investment opportunities in an underserved market with enormous potential. 
  • 11:00 AM | AI in Healthcare: Discover how AI is reshaping drug development and care delivery. 
  • 1:00 PM | Orphan & Rare Diseases Panel: Learn about unique challenges and opportunities in niche, high-need markets. 
  • 2:00 PM | Corporate VC Panel: Hear how corporate venture capital balances strategic and financial goals to accelerate innovation. 
  • 3:00 PM | Techbio & Synthetic Biology Panel: Explore investment trends at the intersection of biology and technology. 
  • 4:00 PM | 2026 Outlook: VC Perspectives Panel: Gain insight into where investors see healthcare innovation heading in the coming year. 

These panels are designed not only to share insights but also to foster dialogue between investors and innovators. If you are interested in speaking on a RESI JPM investor panel, please reach out here. 

Registration for RESI JPM 2026 is now open, with Early Bird rates available until October 24. Don’t miss your chance to connect with top investors, strategic partners, and fellow innovators at one of the premier life science partnering events. Register for RESI JPM 2026 

Register for RESI JPM >>

Tags: , , , , , , , , , ,

LSN Staff on Global Event Circuit; Find Out Who, What, and Where

30 Sep

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is on the move. Between now and RESI London, our team will be attending a series of leading life science and medtech conferences around the world, connecting with innovators, investors, and strategic partners. Getting out into the global ecosystem allows us to better understand emerging trends, foster collaborations, and support life science companies in reaching their fundraising and partnership goals.

These engagements also reinforce the value of our global conference, RESI, which brings together investors, entrepreneurs, and strategic partners from across the world to drive innovation in life sciences. Attending regional and international events helps us strengthen these connections and grow our global community.

Here’s where you can find our team in the coming months:

October 
Oct. 4–8: San Diego for the MedTech conference, engaging with medical device innovators and investors. San Diego, CA
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
Oct. 4–8: LSN Bootcamp and BioSpain, connecting with early-stage life science companies. Barcelona, Spain
  • Greg Mannix (g.mannix@lifesciencenation.com)
  • Karen Deyo (k.deyo@lifesciencenation.com)
  • Brenda Olmos (b.olmos@lifesciencenation.com)
Oct. 8–10: Japan for BioJapan, focusing on international biotech partnerships. Yokohama, Japan
  • Dennis Ford (dford@lifesciencenation.com)
  • Claire Jeong (c.jeong@lifesciencenation.com)
  • Momo Yamamoto (m.yamamoto@lifesciencenation.com)
Oct. 21-23: Sao Paulo for Corporate Venture in Brazil 2025, highlighting innovation and investment opportunities in Latin America. Sao Paulo, Brazil
  • Dennis Ford (dford@lifesciencenation.com)
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
Oct 24-25: Washington DC for the 9th Annual KAPAL Conference, meeting global leaders in biotech and healthcare. Washington DC
  • Sougato Das (s.das@lifesciencenation.com)
Oct. 27–28: Miami for the BioHunt Summit, meeting emerging life science startups and investors. Miami, FL
  • Dennis Ford (dford@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)
November 
Nov. 2–6: Vienna for BioEurope, connecting with corporate and venture partners across the life science ecosystem. Vienna, Austria
  • Max Braht (m.braht@lifesciencenation.com)
  • Greg Mannix (g.mannix@lifesciencenation.com)
Nov. 12–14: Malta at the MedTech World Summit, exploring opportunities in medical technology. Valletta, Malta
  • Greg Mannix (g.mannix@lifesciencenation.com)
  • Brenda Olmos (b.olmos@lifesciencenation.com)
Nov. 16–20: London for Jefferies London Life Sciences Week, engaging with global investors and biotech innovators. London, UK
  • Max Braht (m.braht@lifesciencenation.com)
  • Greg Mannix (g.mannix@lifesciencenation.com)
December 
Dec. 2: France for Biofit/Medfit, meeting early-stage innovators and strategic partners in biotech and medtech. Strasbourg, France
  • Max Braht (m.braht@lifesciencenation.com)
  • Matt Stanton (m.stanton@lifesciencenation.com)

We look forward to seeing our community at these events. If you’d like to connect with us while we’re on the road, please reach out to resi@lifesciencenation.com

Tags: , , , , , , , , , , , ,

Finalist in the RESI Boston Innovator’s Pitch Challenge – Meet M6P Therapeutics

30 Sep

In this interview, Caitlin Dolegowski speaks with Cuong Do, Founder and Chairman of M6P Therapeutics, about the company’s groundbreaking lysosomal targeting platform, its applications in rare disease and oncology, and the experience of pitching at RESI Boston.

Cuong Do
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): M6P Therapeutics has achieved what was long thought impossible, delivering proteins to lysosomes. Can you explain the significance of this breakthrough?

Cuong Do (DO): An enzyme called GlcNac-1-phosphotransferase (PTase) is responsible for adding mannose 6-phosphate to the surface of lysosomal enzymes. People have tried and failed for decades to increase the expression of M6P, and everybody gave up. Our co-founder Stuart Kornfeld never gave up. He and his post-doc were able to engineer a variant of PTase that turned out to be 20X more effective than PTase itself in adding M6P to lysosomal enzymes. We built upon this breakthrough to create a platform that is able to create enzyme replacement therapies that have very high M6P content. Furthermore, our gene therapies are the only ones that result in M6P-containing enzymes being produced by the transduced cells.

We expanded upon the innovation and created chimeric antibodies that contain M6P as well. This allows these antibodies (after they bind to the targeted antigens) to be brought to lysosomes in virtually all cells in our bodies for degradation. This is a significant advantage over traditional antibodies relying on Fc clearance by only select immune cells.

CD: You have multiple rare pediatric drug designations and two programs nearing the clinic. What are the most exciting upcoming milestones for your pipeline?

DO: We are preparing to start an Investigator Initiated Trial in Australia for our M021 ERT for Pompe Disease in hopes of obtaining early human data demonstrating M021’s superiority over the standard of care.

CD: How does your lysosomal targeting platform extend beyond rare diseases, particularly in oncology with your chimeric PD-L1 and PD-1 antibodies?

DO: We figured out a way to add M6P to any protein, including antibodies. Our chimeric antibodies can be cleared by virtually all cells in the body since virtually all cells have receptors for M6P. This is especially effective for clearing surface antigens from cell surfaces. Our chimeric PD-L1 antibody is able to clear virtually all PD-L1 from the surface of tumor cells and thus activate T-cells and drive T-cell mediated tumor killing. Our chimeric version of Keytruda is able to remove PD-1 from the surface of T-cells and has shown to be more effective in inhibiting tumor growth in vivo than Keytruda itself.

CD: Can you walk us through your IP position and how it supports your growth strategy?

DO: We have invested heavily in IP that has created a portfolio of 9 patent families, 9 issued patents, and ~20 still in prosecution.

CD: Where are you in your fundraising journey, and what types of investors or partners are you looking to engage with?

DO: We have raised ~$40 million in our Seed and A rounds, which we invested to get our programs to where they are today. We are trying to raise a $5 million bridge now in anticipation of a $50+ million Series B next year. In addition to investors, we want to engage with potential partners who might be interested in our molecules.

CD: How did participating in the Innovator’s Pitch Challenge at RESI Boston help advance your business development or investor connections?

DO: We met a few companies who might be interested in partnering on some of our molecules. We’re continuing the conversations.

IPC Applications are now open for the next Innovator’s Pitch Challenge at RESI London 2025 and RESI JPM 2026, with spots filled on a rolling basis.

Tags: , , , , , , , , , , , , , , , , , ,

← Older Entries
Newer Entries →